TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02851914
Drug: Tricyclic Antidepressants (TCA)
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: if patient shows signs of depression they will be placed on one of these medications and seen by a psychiatrist.
Study: NCT03727867
Drug: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral EGFR TKI begins on day 1 and continues until disease progresses.
Study: NCT01810952
Drug: Lispro insulin
Normalized name: Lispro insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: In both protocols lispro insulin was given to cover meals. Additional lispro insulin was Lispro insulin was administered before meals to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro Insulin Arm.
Study: NCT01810952
Drug: NPH Insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin was given once or twice a day to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro/NPH Insulin Arm
Study: NCT00221104
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00876343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered orally once daily, 6 weeks
Study: NCT00543465
Drug: MK0782
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02411955
Drug: Tazorac®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazorac® applied to lightly cover the entire face once daily for 84 consecutive days.
Study: NCT02411955
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle of the test product) applied to lightly cover the entire face once daily for 84 consecutive days.
Study: NCT02898506
Drug: Victoza®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
Study: NCT02898506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
Study: NCT02336503
Drug: BBI-4000 Gel, 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBI-4000 Gel, 5%
Study: NCT02336503
Drug: BBI-4000 Gel, 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBI-4000 Gel, 10%
Study: NCT02336503
Drug: BBI-4000 Gel, 15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBI-4000 Gel, 15%
Study: NCT02336503
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, BBI-4000 Gel, 0%
Study: NCT01690247
Drug: Conventional plus UC-MSC
Normalized name: Astri-UC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
Study: NCT01690247
Drug: Conventional plus placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
Study: NCT00692016
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered under fasting condition
Study: NCT00692016
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered under fed condition
Study: NCT03117270
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: one placebo oral tablet q.d.
Study: NCT03695835
Drug: Immunotherapeutic Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antigen exposure immediately followed by in situ injection of combination of immunotherapeutic agents
Study: NCT02229604
Drug: HRT, DHEA and herb
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT, dehydroepiandrosterone (DHEA) and herb decoction could be used for this group. Time frame of treatment is not fixed. Herb decoction will be given to participants based on the principle of syndrome differentiation (a diagnosing method in Traditional Chinese Medicine).
Study: NCT01015196
Drug: Zavedos
Normalized name: Zavedos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01786109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will match study drug; taken as one dose orally with water.
Study: NCT00818844
Drug: Nepafenac 0.1%
Normalized name: NEPAFENAC 0.1% SUSP,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID
Study: NCT00009893
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00009893
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00894647
Drug: placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: cream applied once daily for two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
Study: NCT01967875
Drug: Capecitabine+Cisplatin
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cisplatin 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles.Capecitabine is to be continued until disease progression or intolerable toxicity.
Study: NCT01967875
Drug: Docetaxel+Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Docetaxel 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles. Capecitabine is to be continued until disease progression or intolerable toxicity.
Study: NCT01281306
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 was supplied as tablets in blister cards in 100 mg strengths.
Study: NCT01281306
Drug: AHU377
Approvals — FDA: no, EMA: no, PMDA: no
Description: AHU377 was supplied in tablets in blister cards in 50 mg and 100 mg strengths.
Study: NCT01281306
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied as tablets in blister cards.
Study: NCT00103506
Drug: Doxorubicin hydrochloride (DOXIL/CAELYX)
Normalized name: doxorubicin Injection [Caelyx]
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mg/m\^2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.
Study: NCT00538538
Drug: vitrectomy with subretinal lucentis
Approvals — FDA: no, EMA: no, PMDA: no
Description: A gas bubble will be placed in the eye after the gel has been removed.
Study: NCT00538538
Drug: vitrectomy with subretinal lucentis
Approvals — FDA: no, EMA: no, PMDA: no
Description: These patients will have a vitrectomy where the gel is removed but will not receive the gas bubble.
Study: NCT03435744
Drug: Simvastatin 20 mg
Normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 20 mg added to TAU for 3 months.
Study: NCT00890721
Drug: SKY0402
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the operation, 30cc of SKY0402 are injected into the wound.
Study: NCT00890721
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the hemorrhoidectomy, 30cc Placebo injected into the wound.
Study: NCT01030575
Drug: Inositol lower volume
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
Study: NCT01030575
Drug: Inositol mid-level volume
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
Study: NCT01030575
Drug: Inositol high volume
Normalized name: Inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
Study: NCT01030575
Drug: Placebo low volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose 5% given in volumes equal to that of the comparator drug
Study: NCT03880409
Drug: 2% lidocaine with 1:000,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with 1:000,000 epinephrine is dental local anesthesia
Study: NCT03880409
Drug: 4% articaine with 1:000,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% articaine with 1:000,000 epinephrine is dental local anesthesia
Study: NCT02384460
Drug: SD-101-6.0 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: applied topically once a day for 90 days
Study: NCT02384460
Drug: Placebo (SD-101-0.0) cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: applied topically once a day for 90 days
Study: NCT00373711
Drug: F-18 FDG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-15 mCi, iv
Study: NCT00815737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 days of Placebo
Study: NCT01830699
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 cc (40 mg/mL) triamcinolone intra-bursal once
Study: NCT03110276
Drug: EYP001a
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg and 100 mg capsules. Number of capsules to be ingested will depend on the dose cohort. Administered orally once daily. Single dose (SAD) or 14 days treatment (MAD).
Study: NCT03110276
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, identical in appearance to the EYP001a 10 mg and 100 mg capsules.
Study: NCT00556959
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets for 8 weeks
Study: NCT02421510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once daily, before the first meal of the day
Study: NCT01843881
Drug: Exendin 9, 39
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
Study: NCT01843881
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A saline infusion will be given to match the study drug infusion.
Study: NCT01294540
Drug: Drug: E2609
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2609 orally at varying ascending doses
Study: NCT01294540
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT01311661
Drug: Placebo twice daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Placebo of Olodaterol twice daily
Study: NCT01806792
Drug: risedronate combine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01806792
Drug: Placebo(for Risedronate)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01806792
Drug: Placebo(for risedronate combine)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01972828
Drug: FLUID MANAGEMENT GUIDED WITH PRELOAD-DEPENDENCE PARAMETERS (VOLUVEN ®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: in this arm, fluid loading is administered with an algorithm using preload dependence indexes. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
Study: NCT01972828
Drug: STANDARD-GUIDED FLUID MANAGEMENT (VOLUVEN ®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: in this arm, fluid loading is administered with an algorithm using central venous pressure. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
Study: NCT02094235
Drug: E6005 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02094235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g placebo ointment
Study: NCT02094235
Drug: E6005 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02953054
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching patches that have no active drug applied before surgery and worn for 72 hours.
Study: NCT01873885
Drug: Placebo Single IV (Intravenous) Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride - 30 minute IV infusion
Study: NCT00629239
Drug: AZD4818
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry Powder, inhalation, b.i.d., 4 weeks
Study: NCT00629239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00242476
Drug: MK0822A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03044561
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally, 4 times per day for 21 days
Study: NCT01260753
Drug: UR-63325
Approvals — FDA: no, EMA: no, PMDA: no
Description: UR-63325
Study: NCT01260753
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to UR 63325 and fluticasone propionate nasal spray
Study: NCT04333823
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic Dapagliflozin 5mg tablet
Study: NCT00186797
Drug: Fludarabine, Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02661971
Drug: Calciumfolinat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leucovorin 200 mg/m², d1
Study: NCT01937338
Drug: AZD7624
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebuliser solution; 20 mg/mL for inhalation
Study: NCT01937338
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebuliser solution for inhalation
Study: NCT01084720
Drug: V0034 CR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01542099
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during double lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. And, step size of dose is 0.5ng/ml.
Study: NCT01542099
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during single lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.~For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. Step size of dose is 0.5ng/ml.
Study: NCT01851512
Drug: T-R (Test-Reference drug)
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01851512
Drug: R-T (Reference-Test drug)
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01877954
Drug: Extra-fine hydrofluoroalkane beclometasone dipropionate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01651598
Drug: Placebo to BI 144807
Approvals — FDA: no, EMA: no, PMDA: no
Description: multiple dose (bid)
Study: NCT02273453
Drug: Songha® Night
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02273453
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02337946
Drug: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Study: NCT02337946
Drug: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01873833
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01873833
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01449487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for administration in the rectum Identical tp active solution but without active drug
Study: NCT02068599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment matching active intervention administered twice a day (morning and evening) to target knee. Participants were provided with a laminated instruction sheet including pictures that both described and illustrated how the ointment was to be spread over the entire knee anteriorly, medially, and laterally in a thin layer that fully covered the area. The ointment was gently massaged into the skin.
Study: NCT02286830
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid will be given to all participants for two years. Then patients will be randomized to A receive 2 more years of treatment or B stop treatment.
Study: NCT00291915
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01106950
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered as a 2 hour intravenous infusion with high volume fluid flush and mesna per institutional guidelines on day -5 and -4 one hour after fludarabine infusion. (Day -4 administration may be omitted if patient has had a transplant in the previous 4 months.)
Study: NCT00448149
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD001 will be administered orally once a day, daily, without interruption per 4 wk cycle for 2 cycles. MTD is established in Phase I portion of trial (2.5, 5 or 10mg). If responding, additional therapy will be given.
Study: NCT03346317
Drug: estradiol valerate tablets+dydrogesterone tablets
Normalized name: dydrogesterone / estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral estradiol valerate tablets+dydrogesterone tablets
Study: NCT01870037
Drug: Placebo (PBS-20% sucrose)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01870037
Drug: hMaxi-K
Normalized name: Effer-K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment/2 escalating dose levels (16000 µg and 24000 µg by intramuscular injection)
Study: NCT03336866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT03336866
Drug: IXT-m200
Approvals — FDA: no, EMA: no, PMDA: no
Description: IXT-m200 is an anti-methamphetamine monoclonal antibody
Study: NCT02049879
Drug: Corticosteroids injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: A solution of triamcinolone 40 mg (Kenalog) mixed with 3 cc of 2% xylocaine without epinephrine.
Study: NCT03402087
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT03402087
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT03923842
Drug: Chemotherapy as clinical standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Gemcitabine will continue for 12 months if the patient will not shown disease progression
Study: NCT00541775
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo - administered as one placebo tablet to match Sitagliptin 100 mg and two placebo capsules to match rosiglitazone 4 mg once daily in the morning for up to 18 weeks.
Study: NCT04518410
Drug: Placebo for BRII-196+BRII-198
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.
Study: NCT04518410
Drug: Placebo for SNG001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trisodium citrate dihydrate, di-sodium hydrogen-phosphate, sodium dihydrogen-phosphate dihydrate, racemic methionine (DL-methionine) and water. 1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.
Study: NCT02478788
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pills with no medication in it
Study: NCT02084342
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100ml, IV for 30min,before incision.
Study: NCT00669344
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.
Study: NCT00002874
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
Study: NCT04113993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identically packaged placebo capsule daily
Study: NCT01980888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match idelalisib administered orally twice daily
Study: NCT03018938
Drug: Insulin Analog Mid Mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03018938
Drug: Basal Insulin Analog
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04230070
Drug: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioequivalence
Study: NCT04230070
Drug: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioequivalence
Study: NCT04441398
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo TID for 7 days. Treatment can be extended for another 7 days at Investigators discretion.
Study: NCT03679884
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo film-coated tablets
Study: NCT00723242
Drug: Viraferon-peg and Rebetol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00494156
Drug: heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01408498
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical administration of testosterone gel. Participants receive a one-time, single dose of 10 g of 1% testosterone gel.
Study: NCT00504309
Drug: 4/day of 4g P-OM3 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4/day of 4g P-OM3 capsules for 8 weeks
Study: NCT00504309
Drug: 4/day of 1g P-OM3 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4/day of 1g P-OM3 capsules for 8 weeks